Depending on the pathology and the genetic predisposition of the patient, stem cell therapy or a combination of gene and stem cell therapies may be beneficial. Because of this we are involved in the development of cell therapy technology in parallel with gene therapy. We are currently working towards the demonstration of the safety and efficacy of stem cell therapy for Duchenne muscular dystrophy and acute cerebral infarction in animal models of the disease. In the case of Duchenne muscular dystrophy, sponsor-initiated clinical trials began in 2023.